The latest biotech news - Labiotech.eu

Home News and Trends Page 253

Latest Posts

News and Trends 26 May 2017

UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy

UPDATE (26/05/2017): GW has released more positive results in The New England Journal of Medicine demonstrating that Epidiolex dramatically reduces convulsive seizures in children with Dravet syndrome. The results have primed the drug for its NDA submission to the FDA and led some to forecast blockbuster success. Original Publication 30/03/2016 GW Pharmaceuticals (UK) has announced positive results […]

May 26, 2017 - 4 minutesmins - By Ekaterina Perets

research embl breast cancer relapse

News and Trends 25 May 2017

Resilient Tumor Cells Drive Breast Cancer Relapse in Mice

Tumor cells that survive chemotherapy and drive breast cancer relapse may provide drug targets for potential treatments to reduce the recurrence. In mice, some breast tumor cells can survive chemotherapy and drive the recurrence of tumor, found a team of researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and in Monterotondo, Italy; […]

May 25, 2017 - 3 minutesmins - By External Contributor

shutterstock 646009759 2

News and Trends 24 May 2017

UK biotech is catching up to the US, but will it run out of gas?

The UK is far ahead of its European biotech rivals according to a new report, but will it fulfill its promise of becoming a global hub? According to analysis by the BioIndustry Association, the UK is catching up to global biotech leaders San Francisco and Boston, both in finance and R&D. British biotechs banked £1.13B last year, and […]

May 24, 2017 - 5 minutesmins - By Evelyn Warner

ose selexis ibd effi 7 agreement

News and Trends 24 May 2017

French Biotech Enters New Agreement to Advance its IBD Immunotherapy

OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist for the treatment of IBD. In the end of last year, French OSE Immunotherapeutics joined forces with Servier to develop and commercialize its interleukin-7 antagonist (Effi-7) in a deal that could earn the biotech up […]

May 24, 2017 - 3 minutesmins - By Melanie De Almeida

shutterstock 609674213

News and Trends 24 May 2017

Curious about Who is Living in Your Gut? This Kit Can Tell You

Personalized and democratized medicine is coming to the microbiome via a new initiative, FeelGut, from Biopolis. The FeelGut kit lets you explore your gut! FeelGut is a new kit for those of us who want to explore their microbiota. It’s developed by Biopolis, a Spanish biotech committed to empowering people through improved understanding and control of […]

May 24, 2017 - 3 minutesmins - By External Contributor

Oryx glioblastoma ParvOryx combination 1

News and Trends 23 May 2017

German Biotech Tops Up its Oncolytic Virus with Immuno-Oncology Drugs

Oryx has reported good clinical data on the combination of its oncolytic virus with immuno-oncology drugs, convincing the biotech to start clinical trials. Based in Munich, Oryx is developing cancer immunotherapies for a number of solid tumors consisting of oncolytic viruses and peptide vaccines. The company just announced positive clinical data for 16 patients treated under compassionate use […]

May 23, 2017 - 2 minutesmins - By Melanie De Almeida

ADVERTISEMENT

Merck Ablynx nanobody osteoarthritis

News and Trends 23 May 2017

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the same properties as antibodies but with the advantage of being much smaller. This technology has attracted top pharma partners like AbbVie, MSD, Boehringer Ingelheim and Novartis. Now, the third […]

May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

BerGenBio BGB324 Melanoma Phase i ii 2

News and Trends 22 May 2017

Norwegian Biotech Goes for Combination Therapies in Melanoma

BerGenBio has started a new Phase I/II trial evaluating the addition of its Axl inhibitor to standard of care treatments in advanced melanoma. In March, Norwegian BerGenBio beat a biotech record on the Norwegian stock exchange, raising a massive €43.55M. Now, the company is standing by its promises and just dosed the first patient in a […]

May 22, 2017 - 2 minutesmins - By Melanie De Almeida

argenx llama antibody immuno oncology IPO

News and Trends 22 May 2017

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial goal. Rather a lot for a company whose compound has yet to prove itself in Phase II. UPDATE (24/04/2017): Pricing terms have yet to be set, but the […]

May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Guy Ben Ary cellf concert neuron

News and Trends 20 May 2017

A Concert Played by Human Neurons on a Petri Dish

Guy Ben-Ary grew his own neurons on a Petri dish and made them perform in a concert last weekend at the Haus der Kulturen der Welt in Berlin. Last weekend I took my bike across Berlin to attend a truly unique event. It was, in fact, my first time going to a concert where one […]

May 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Iterum Therapeutics antibiotics series b fundraising

News and Trends 19 May 2017

Irish Biotech developing New Antibiotics attracts €58M in Series B Round

Iterum Therapeutics has raised €58M to fund Phase III and bring a new antibiotic to a market where innovation is lacking. Iterum Therapeutics is a biotech based in Dublin that develops new antibiotics with the aim of combating the superbug crisis. The company has just raised €58M ($65M) in Series B to fund Phase III […]

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

cell resonance optogenetics turku

News and Trends 19 May 2017

Shining new Light on how to control Cell Circuits

Controlling genes with light is a new therapeutic avenue, and researchers from Finland are exploring how it can be used to tinker with the cell’s biochemical circuitry. Their findings could provide a better understanding of degenerative diseases and yield new cancer treatments. Researchers from the Turku Centre for Biotechnology at the University of Turku and Åbo […]

May 19, 2017 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT